Latest Financial Sustainability News

Avenira Limited has obtained a $5 million unsecured loan to fund key mining projects and maintain working capital while awaiting a strategic investment approval.

FBR Limited reports a significant reduction in half-year losses alongside new robotic product launches, yet cash flow challenges raise questions about its financial sustainability.

I Synergy Group Limited reported a 15.63% drop in revenue to AUD 0.81 million for FY2025, alongside a 21.5% increase in net loss to AUD 0.34 million, with auditors flagging going concern uncertainties.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

Aland Equity Group reported a sharp revenue decline and an 85% increase in losses for the half-year ending December 2025, while completing a major capital raise and reshuffling its board.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

ZMM has reported a remarkable 253% increase in revenue for the half-year ending December 2025, yet still recorded a net loss of $1.078 million amid concerns over its financial sustainability.

Prime Financial Group has reported a robust first half of FY26, with revenue climbing 31% and underlying EBITDA soaring 60%, driven by strategic acquisitions and organic growth.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

G8 Education has announced a significant $350 million goodwill impairment for FY25, reflecting ongoing sector pressures. Despite this, the company maintains its EBIT guidance but suspends dividends and pauses its share buyback program.

Tusker Minerals reported a solid financing inflow of A$4.455 million in the December quarter, offsetting significant cash outflows from exploration and setup costs, leaving the company with A$2.2 million in cash and nearly two quarters of funding runway.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.